Movement Disorder Agents

WA.PHAR.51 Movement Disorder Agents

Background:
Huntington’s disease is a genetic, progressive, neurodegenerative disorder clinically characterized by a triad of motor, cognitive and psychiatric symptoms. Motor features include involuntary jerking or writhing movements (chorea) and voluntary movements; reduced manual dexterity, slurred speech, swallowing difficulties, balance problems and falls. Signs and symptoms develop in their 30s or 40s for most people but the disease may emerge earlier or later in life.

Tardive dyskinesia is a neurological disorder caused by the long-term use of neuroleptic drugs, or anti-psychotic medications that result in involuntary, repetitive body movements. The symptoms may include grimacing, sticking out the tongue, smacking of the lips, rapid jerking movements or slow writhing movements.

Medical necessity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>deutetabrbenzine (AUSTEDO™) tetrabenazine (XENAZINE®)</td>
<td>Deutetabrbenzine and tetrabenazine may be considered medically necessary for the diagnosis of chorea associated with Huntington’s disease or tardive dyskinesia.</td>
</tr>
<tr>
<td>valbenazine (INGREZZA®)</td>
<td>Valbenazine may be considered medically necessary for the diagnosis of tardive dyskinesia</td>
</tr>
</tbody>
</table>

Clinical policy:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical Criteria (Initial Approval)</th>
</tr>
</thead>
</table>
| deutetabrbenzine (AUSTEDO™) tetrabenazine (XENAZINE®) | 1. Diagnosis of ONE of the following:  
   a. Chorea associated with Huntington’s disease  
   b. Tardive dyskinesia  
   2. Greater than or equal to (≥) 18 years of age  
   3. Not used in combination with another vesicular monoamine transporter 2 (VMAT2) -inhibitor (e.g. tetrabenazine, deutetabrbenzine, valbenazine)  
   4. NONE of the following:  
      a. Hepatic impairment  
      b. Concurrent use or recent discontinuation of MAOIs or reserpine  
   5. Prescribed by or in consultation with a psychiatrist or neurologist  
   6. For deutetabrbenzine only:  
      a. Less than or equal to (≤) 48mg per day  
   7. For tetrabenazine only  
      a. ONE of the following dose limits: |

Policy: Movement Disorder Agents

Last Updated 02/21/2018
i. Diagnosis of Chorea associated with Huntington’s disease less than or equal to (≤) 50mg per day

1) For doses, greater than 50mg per day genotyping for CYP2D6 is required to determine if client is an intermediate or extensive metabolizer.

ii. Diagnosis of tardive dyskinesia less than or equal to (≤) 200mg per day

Valbenazine (INGREZZA®)

1. Diagnosis of tardive dyskinesia
2. Greater than or equal to (≥) 18 years of age
3. Not used in combination with another vesicular monoamine transporter 2 (VMAT2) -inhibitor (e.g. tetrabenazine, deutetrabenazine, valbenazine)
4. Less than or equal to (≤) 80mg per day
5. NONE of the following:
   a. History of congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval
   b. History of severe renal impairment
   c. Concomitant use with MAOIs.
6. Prescribed by or in consultation with a psychiatrist or neurologist

Apprõve for 12 months

Criteria (Reauthorization)

Documentation of positive clinical response

Approve for 12 months

Dosage and quantity limits

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose and Quantity Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deutetrabenazine (AUSTEDO™)</td>
<td>48mg per day;</td>
</tr>
<tr>
<td>Tetrabenazine (XENAZINE®)</td>
<td>HD Chorea:</td>
</tr>
<tr>
<td></td>
<td>• Extensive/intermediate metabolizers: 100 mg/day</td>
</tr>
<tr>
<td></td>
<td>• Poor metabolizers: 50 mg/day</td>
</tr>
<tr>
<td>Valbenazine (INGREZZA®)</td>
<td>TD: 200mg per day;</td>
</tr>
<tr>
<td></td>
<td>80mg per day;</td>
</tr>
</tbody>
</table>

References


Policy: Movement Disorder Agents

Last Updated 02/21/2018